首页|大补元煎加味联合聚乙二醇化重组人粒细胞集落刺激因子对含铂双药化疗后Ⅲ、Ⅳ度骨髓抑制患者的临床效果

大补元煎加味联合聚乙二醇化重组人粒细胞集落刺激因子对含铂双药化疗后Ⅲ、Ⅳ度骨髓抑制患者的临床效果

扫码查看
目的 探讨大补元煎加味联合聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)对含铂双药化疗后Ⅲ、Ⅳ度骨髓抑制患者的临床效果.方法 选取150例含铂双药化疗后Ⅲ、Ⅳ度骨髓抑制患者,将其随机分为对照组和研究组,每组75例.对照组行PEG-rhG-CSF治疗,研究组在对照组的基础上行大补元煎加味治疗,两组均持续用药21d.比较两组血常规指标、T淋巴细胞亚群、生活质量和治疗期间不良反应的发生情况.结果 治疗21d后,研究组白细胞、中性粒细胞、CD3+、CD4+水平和CD4+/CD8+,以及生存质量测定量表生理领域评分、心理领域评分、社会领域评分与环境领域评分均高于对照组,CD8+水平低于对照组(均P<0.05).两组治疗期间不良反应的发生情况差异无统计学意义(P>0.05).结论 大补元煎加味联合PEG-rhG-CSF可改善含铂双药化疗后Ⅲ、Ⅳ度骨髓抑制患者的血常规指标,纠正T淋巴细胞紊乱,改善生活质量.
Clinical effect of supplemented Dabu Yuanjian combined with PEGylated recombinant human granulocyte colony stimulating factor in patients with grade Ⅲ or Ⅳ myelosuppression after platinum-based doublet chemotherapy
Objective To investigate the clinical effect of supplemented Dabu Yuanjian combined with PEGylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF)in patients with grade Ⅲ or Ⅳ myelosuppression after platinum-based doublet chemotherapy.Methods A total of 150 patients with grade Ⅲ or Ⅳ myelosuppression after platinum-based doublet chemotherapy were selected and randomly divided into the control group or the study group,with 75 cases in each group.The control group was treated with PEG-rhG-CSF,based on which the study group was treated with modified Dabu Yuanjian additionally,and both groups continued the medication for 21 days.The blood routine examination indexes,T lymphocyte subsets,quality of life,and the incidence of adverse reactions during treatment were compared between the two groups.Results After 21 days of treatment,the leukocyte,neutrophil,CD3+,and CD4+levels;CD4+/CD8+;and scores in 4 domains of the World Health Organization Quality of Life scale(physical health,psychological,social relationships,and environmental health)in the study group were higher than those in the control group,and the CD8+level was lower than that in the control group(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Supplemented Dabu Yuanjian combined with PEG-rhG-CSF can improve the blood routine examination results,correct T lymphocyte disorders,and improve the quality of life for patients with grade Ⅲ or Ⅳ myelosuppression after platinum-based doublet chemotherapy.

Modified Dabu YuanjianPEGylated recombinant human granulocyte colony stimulating factorMyelosuppressionBlood routine examinationT lymphocyte subset

尤海玲、陈源、陈丽萍

展开 >

北京中医药大学深圳医院(龙岗)肿瘤科,广东省深圳市 518172

大补元煎加味 聚乙二醇化重组人粒细胞刺激因子 骨髓抑制 血常规 T淋巴细胞亚群

希思科-齐鲁肿瘤研究基金(2019)

Y-QL2019-0326

2024

内科
广西壮族自治区医学科学情报研究所

内科

影响因子:0.905
ISSN:1673-7768
年,卷(期):2024.19(1)
  • 23